From development in the laboratory to production in the clean room: the Institute for Cell Therapeutics offers researchers advice and assistance in the production of new cell therapies. Copyright: Karin Kaiser/MHH
From development in the laboratory to production in the clean room: the Institute for Cell Therapeutics offers researchers advice and assistance in the production of new cell therapies. Copyright: Karin Kaiser/MHH The ATMP-GMPDU development unit at the Institute for Cell Therapeutics supports research groups in the development of new cellular drugs. Using living cells for therapy is a promising alternative when classical treatment methods fail in the fight against the most severe diseases. In addition to stem cell transplantation, therapies using genetically modified cells have now also been approved in Europe as so-called advanced therapy medicinal products. They are called Advanced Therapy Medicinal Product or ATMP for short. In order to prevent contamination with pathogens or undesirable effects, ATMPs must be manufactured under strictly controlled conditions in accordance with the high quality specifications of good manufacturing procedure (GMP) under cleanroom conditions. This is done at the MHH at the Institute for Cell Therapeutics, in the Cellular Therapy Centre (CTC) department.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
